Human herpesvirus (HHV)-6A or HHV-6B involvement in multiple sclerosis (MS) etiology 33 has remained controversial mainly due to the lack of serological methods that can distinguish 34 the two viruses. 35
INTRODUCTION 56
Human herpesvirus 6A (HHV-6A) and HHV-6B are closely related beta-herpesviruses with 57 distinct biological and immunological properties as well as differences in epidemiology and 58 disease associations (1) . HHV-6B is acquired early in life (2, 3), with the vast majority of 59 children infected before the age of two. Primary HHV-6B infection results in roseola, a 60 disease characterized by high fever, rashes and occasional febrile seizures (3) (4) (5) . As with all 61 herpesviruses, HHV-6A and HHV-6B can establish latency and reactivate later in life, which 62
can lead to severe diseases such as encephalitis (reviewed in (6)). Less is known about any 63 clinical manifestations of the primary infection of HHV-6A, but this virus has repeatedly been 64
reported to be associated with multiple sclerosis (MS) (7) (8) (9) (10) (11) (12) . As previous studies have been 65 limited in size or unable to separate the HHV-6A from B serologically, a more definite view 66 on their respective roles in MS would benefit from a comprehensive population based case-67
control study on the diverging serological response against these two viruses. 68 MS is characterized by central nervous system inflammation and demyelination, with several 69 different disease courses: relapsing remitting MS (RRMS), secondary progressive MS 70 (SPMS), and primary progressive MS (PPMS). The etiology of the disease includes a genetic 71 predisposition (13, 14) . Lifestyle/environmental factors, like virus infections and smoking 72 also play a role, and they often interact with MS risk genes (15). Among virus infections, the 73 gamma-herpesvirus Epstein-Barr virus (EBV) has remained the strongest suspect in the MS 74 etiology (16) (17) (18) (19) (20) (21) . Another beta-herpesvirus, cytomegalovirus (CMV), has through serological 75 analysis been negatively associated with MS risk (22) . We here explore the potential 76 associations of HHV-6A and B in MS, and interaction with serological response to EBV and 77 CMV, using serology applied to both a very large incident and prevalent MS case-control 78 material, and importantly, also a pre-MS case-control cohort. 79
Seroconversion against HHV-6 usually occurs in early childhood (23-25) but as the two 80 viruses have similar proteomes, it has been difficult to distinguish anti-HHV-6A from anti-81 HHV-6B antibody responses. This inability is a major concern when investigating virus-82 specific disease associations and a possible explanation for the contradictory associations 83 between HHV-6 IgG response and MS (26-33). However, even though HHV-6A and HHV-84 6B are 90% homologous, there are parts of their genome with more divergence (34, 35) . The 85 immediate-early 1 (IE1) proteins (termed IE1A for HHV-6A and IE1B for HHV-6B), 86
encoded by the open reading frame (ORF) U90-U89, are among the most divergent with only 87 62% homology (36, 37) and with differences in biological properties. IE1A, but not IE1B, 88
can transactivate several heterologous promoters (37, 38) while IE1B, but not IE1A can 89 silence IFN-α/β signaling (39). The ORF U11 coding for p100 in HHV-6A and 101K in 90 HHV-6B also exhibit relatively high divergence with only 81% amino acid identity (40). 91
These structural proteins are essential for viral growth and propagation (41), and 101K has 92 been identified as the dominant antigen recognized by anti-HHV-6B IgG (42) . With the aim 93 to discriminate between IgG responses against these two viruses, we developed a novel bead-94 based multiplex serology assay measuring IgG antibodies against IE1A, IE1B, p100 and 95 101K, selecting the most divergent parts of these protein sequences. This assay was used to 96 screen serum or plasma samples from persons with MS, persons that later develop MS, and 97 controls for HHV-6A and HHV-6B protein-specific antibodies. 98 99 100 HHV-6A in MS
RESULTS 101
High IE1A antibody response is positively associated with MS and is a risk factor for 102 developing MS in youth 103
We used a novel multiplex serology assay to investigate the specific IgG responses against the 104 HHV-6A protein IE1A and the HHV-6B protein IE1B. To investigate if persons with MS and 105 controls differed in IgG responses, logistic regression analyses were used to compare strong 106 and weak responders, defined as the highest or lowest quartile of each measured response. 107
This revealed that a high IE1A antibody response was positively associated with MS (OR = 108 1.55, p = 9x10 -22 ) while a high IE1B antibody response was negatively associated with MS 109 (OR = 0.74, p = 6x10 -11 ) (Table 1, Figures 1A and 1B) . 110
To investigate if these differences also were present before MS onset, serum samples drawn 111 from persons with RRMS at a median of 8.3 years before symptom onset and from matched 112 controls were analyzed. Strong IE1A responders had a higher risk of developing MS later in 113 life, compared to low responders (OR = 2.22, p = 2x10 -5 ) (Table 2, Figure 1D ). No 114 significant difference in IE1B IgG response was observed before MS onset (OR = 0.96, p = 115 0.8) ( Table 2 and Figure 1E ). 116
The pre-MS cohort was divided into age groups and further analyzed ( Table 2 ). In individuals 117 younger than 20 years old, strong IE1A responders had a 3.38 (p = 0.004) times higher risk of 118 developing MS later in life. This MS risk decreased with age, reaching an OR of 1.51 (p = 119 0.3) in the oldest age group (30-39 years) . Also in the established MS cohort the highest OR 120 was seen in the youngest age group ( Table 1) . 121 122
Interaction between high IE1A and EBV antibody responses on MS risk 123
As antibody responses against other herpesviruses such as EBV and CMV have been 124 associated with MS (19, 22) , the interplay between HHV-6A/-6B and these viruses in MS was 125 analyzed. The median antibody levels of EBV and CMV index among controls were used as 126 cutoffs for strong or weak responders. Interaction analyses revealed a significant additive 127 interaction between IE1A and EBV responses on MS risk (attributable proportion due to 128 interaction (AP = 0.24, p = 6x10 -6 , Figure 2A ), meaning that 24% of the risk for developing 129 MS in those with strong IE1A and strong EBV responses was due to interaction between 130 these factors. No significant interaction between HHV-6A and CMV immune response was 131 observed, neither was the HHV-6B IE1B or 101K responses interacting with EBV on MS risk 132 (Figure 2B , SI appendix Figure S1A and B ). An analysis of how the OR varied for the three 133
HHV-6A and B antigens depending on EBV index was investigated using a sliding window 134 approach and shows that IE1A mediated risk for MS is limited to individuals with EBV 135 response higher than the median among controls (SI appendix Figure S2 ). 136 137 Antibody levels against IE1A are higher in both established MS cases and pre -MS cases, 138 compared to matched controls 139 Linear regression models were used to analyze the HHV-6A/6B IgG levels, and the results are 140 in line with the association seen for high/low serological response. MS cases, both before 141 (pre-MS) and after MS onset (established MS), had higher IgG levels against IE1A than 142 controls (p = 6x10 -10 and p = 9x10 -30 , respectively; Figure 1 , Table S1 and S2 in  143 Supplementary Material). In contrast, anti-IE1B IgG levels were lower in established MS 144 cases compared to controls (p = 9x10 -14 ), but this association was not observed before MS 145
onset. When dividing the study cohorts into age groups, IE1A reactivity was consistently 146 higher in MS cases compared to in controls (Figure 3A and B) , while the pattern for the anti-147 IE1B reactivity was more inconsistent ( Figure S3A -D in Supplementary Material). The 148 associations of IE1A with MS were significant both with and without adjustment for EBV and 149
CMV responses, indicating that the increased IE1A response in MS was not confounded by 150
these two anti-viral responses (Table S1 and S2 in Supplementary Material). In addition to the 151 IE proteins, antibodies against the structural protein 101K (HHV-6B) and p100 (HHV-6B) 152
were measured. A high 101K serological response was not associated with MS or with later 153 development of MS in the pre-MS cohort ( Table 1 and 2). Results from the p100 analysis 154
were excluded from further analyses due to the low reactivity against this antigen. 155 156 High IE1A response is associated with relapsing and progressive MS, but not disease 157 severity 158
The association of high IE1A responses was similar regardless of disease course (OR RRMS = 159
1.62, p = 1x10 -20 ; OR SPMS = 1.49, p = 7x10 -7 ; OR PPMS = 1.53, p = 9x10 -4 ). The same was true 160
for high IE1B responders (OR RRMS = 0.77, p = 2x10 -6 ; OR SPMS = 0.67, p = 2x10 -6 ; OR PPMS = 161 0.62, p = 7x10 -4 ). A high 101K response was associated with RRMS (OR = 1.18, p = 1x10 -3 ), 162 but negatively associated with PPMS (OR = 0.66, p = 2x10 -3 ). 163 HHV-6A and 6B serology was not associated with two MS severity scores, the Multiple 164
Sclerosis Severity Score (MSSS) and the Age Related Multiple Sclerosis Severity Score 165 (ARMSS) (43) (data not shown). 166
167
The IgG responses against HHV-6B proteins vary with age and sex 168
The level of IgG responses against IE1B and 101K decreased with age (p = 4x10 -21 and p = 169 3x10 -39 , respectively; Figure S3A -D in Supplementary Material). A sex difference could be 170 observed, with women eliciting a significantly stronger antibody response against IE1B (p = 171 4x10 -4 ) and 101K (p = 2x10 -24 ). Antibody levels against IE1A did not differ significantly 172 between the sexes nor with age. 173 174
Smoking associates with increased IE1A IgG response in persons with MS 175
As smoking has been reported to be a risk factor for MS disease (44) and has been associated 176 with higher HHV-6 IgG levels (32), the effect of smoking on HHV-6 protein-specific IgG 177 responses was investigated. Persons with MS and with a history of regular smoking showed 178
higher IE1A IgG levels compared to those who never smoked (p = 2x10 -5 ). This was not 179 observed in controls (p = 0.4). The responses against the other proteins were not affected by 180 smoking, neither in MS cases nor in controls (data not shown). 181
HHV-6A in MS
IgG responses against HHV-6 proteins are associated with different HLA haplotypes 182
To investigate the influence of genetic factors for the serological response against the HHV-183
6A and HHV-6B protein sequences, genome-wide association studies (GWAS) were 184 performed for both IgG levels (Figure 4 ) and high/low response ( Figure S4 in Supplementary  185 Material). The primary genetic association was mapped to the Human Leukocyte Antigen 186 (HLA) region (6p21). There was a clear difference in IE1A and IE1B response in regard to 187 their association to SNPs located in the HLA region, where IE1A levels were associated (p < 188 5x10 -8 ) with 191 SNPs mapping to the HLA region while IE1B IgG levels were significantly 189 associated with only two SNPs in this region. 190
Deciphering of the associations within the HLA region showed that IgG responses against the 191 three different protein sequences were associated with different HLA haplotypes ( Table 3, 192 Tables S3 and S4 in Supplementary Material). There were some differences between cases 193 and controls, but for most haplotypes the association was stronger when cases and controls 194
were analyzed together ( These associations where also still significant after adjustment for HLA ( Table 3 ). The main 201
HLA association for IE1B was DRB1*13:02-DQA1*01:02-DQB1*06:04, although none of 202 the HLA associations reached the genome wide significance of p < 5x10 -8 (Table S3 in  203 Supplementary Material). Anti-101K response showed associations with several SNPs in the 204 HLA region, but for the individual HLA haplotypes detected, none of them reached genome 205 wide significance of p < 5x10 -8 (Table S4 in Supplementary Material) . 206
Re-analyses were performed adjusting for the most associated HLA allele in each HLA 207 haplotype reported in Table 3, and Tables S3 and S4 in Supplementary Material. The number 208 of significant SNPs (p < 5x10 -8 ) decreased from 191 to 4 in the IE1A GWAS, and no SNP in 209 the HLA locus remained significantly associated with the antibody responses against IE1B 210 and 101K ( Figure S5 and Tables S7 and S8 in Supplementary Material). 211
Although several HLA haplotypes were found to influence anti-HHV-6A/6B protein specific 212
IgG responses, the association between serological responses and MS disease remained to a 213 large extent unaltered when adjusting for carriage of associated HLA alleles (Tables S3 and  214 S4 in Supplementary Material). 215 216
IgG response to HHV-6A and B proteins interacts with MS risk HLA alleles 217
We investigated the interaction between IE1A, IE1B and 101K IgG responses and the major 218 MS risk HLA alleles DRB1*15:01 and A*02:01 in conferring risk to MS. High IgG response 219 to IE1A interacted with both DRB1*15:01 and absence of A*02:01 (AP=0.31, p=2x10 -8 and 220
AP=0.21, p=2x10 -4 respectively) while IE1B only interacted with DRB1*15:01 (AP=0.19, 221 p=1x10 -3 , Figure 5 ). The interaction between IE1A and DRB1*15:01/A*02:01 on MS risk 222 was only observed in persons with high EBV levels, while the IE1B-DRB1*15:01 interaction 223 was only significant in persons with low EBV levels (data not shown). 224
DISCUSSION 225
We show in a large national case-control cohort that persons with MS have higher IgG 226 reactivity against the IE1 protein sequence from HHV-6A compared to controls, while an 227 association in the opposite direction was observed for reactivity against the corresponding IE1 228 protein sequence from HHV-6B. Importantly, the positive association for IE1A was observed 229 also in samples drawn before MS onset, indicating that it is not simply the state of chronic 230 inflammatory disease that induces the higher level of anti-viral antibodies, but that differences 231 in serological status precede clinical symptom onset. Since having a strong IE1A response 232 during adolescence (< 20 years) conferred the highest risk of developing MS on average 10 233 years later in life ( Table 2) , our data argues against a reversed causation. We presume that the 234 increased humoral immune reactivity to the selected viral proteins reflects a more intense 235 primary infection and/or reactivation, resulting in higher viral load and therefore an increased 236
anti-viral response. Assuming that HHV-6A infection does play a role in disease onset, this 237
data suggests that acquisition of HHV-6A at a younger age might play an important role in 238 triggering MS. 239
The positive association seen for HHV-6A (IE1A), but not for HHV-6B (IE1B), with MS 240 disease is in line with some previous studies (8, 10-12) and is interesting considering the 241 differences between the viruses. Both HHV-6A and 6B have the ability to remain latent in the 242 brain (45), but only HHV-6A has been shown to infect and form latent infection in 243
oligodendrocytes (46), the myelin-producing cell and the presumed target of the autoimmune 244 reaction in MS. Speculatively, reactivation of the virus from oligodendrocytes could direct the 245 immune system towards these target cells, suggesting a mechanism that would explain a 246 selective association of HHV-6A with MS. Furthermore, human oligodendrocyte progenitor 247 cells expressing the HHV-6A latency-associated viral protein U94A do not migrate accurately 248
(47), which may yield insufficient myelin repair in the brain and hence could provide another 249 potential link between HHV-6A infection and MS disease. An additional possibility for a 250 potential causative role for HHV-6A in myelin tissue destruction is supported by in vitro data 251
showing that supernatants from HHV-6A, but not from HHV-6B, infected cell cultures induce 252 caspase-independent cell death (e.g. necroptosis) in oligodendrocytes (48). This virus-specific 253 pattern is in line with the data in the present study where increased IE1A, but not IE1B, IgG 254 levels are seen in MS plasma. Thus, an association to HHV-6A gives plausible explanations 255 for both the myelin degradation and impaired re-myelination in MS. 256
Regarding interactions with already established risk factors for MS, we can report an additive 257 interaction between strong IgG responses to IE1A and EBV (Figure 2A) , not seen for IE1B 258 ( Figure S1A in Supplementary Material). This suggest that increased immune response to 259 both viruses are involved in MS and would be consistent with studies reporting that HHV-6A, 260
but not HHV-6B, infection of cells carrying the EBV genome can activate EBV replication 261 (49-51). As HHV-6A infection can activate LMP-1 and EBV nuclear antigen (EBNA)-2 262 protein expression (50), two proteins important for EBV immortalization of B cells, one can 263 speculate that the increased IE1A IgG levels seen in the present study may be a result of 264 increased infection and transformation of EBV infected B cells. However, that would lead to a 265 general increase of antibody of all specificities including the response against IE1B, which we 266 did not find. An interaction between HHV-6A and EBV in MS has been suggested elsewhere 267 (52), where the author hypothesizes that HHV-6A activates latent EBV in B-cells resident in 268 MS lesions and that both viruses, together, are fundamental for the etio-pathogenic processes 269 of MS. We could in addition observe interaction between the main MS HLA risk alleles and 270 IE1A IgG response ( Figure 5 ) indicating that these MS risk factors are acting jointly in 271 HHV-6A in MS increasing risk of MS, at least in a group of patients. Similar interaction with HLA has 272 previously been reported for immune response to EBV (19) . 273
The specificity of the serological response we report here is interesting. As antigens, IE1A 274 proteins are located in the cell nucleus and two relevant questions to consider are how the B-275 cell activates a response against these antigens and what functions these antibodies might 276
have. Increased IgG responses against intra-nuclear herpesvirus proteins in MS have been 277
reported previously for the HHV-6A and 6B protein p41, and the EBV protein EBNA-1 (53, 278 54). For B cells to be directed against nuclear or intracellular antigens the cell needs to be 279 disrupted, for example through necroptosis, a form of immunogenic programmed cell death 280
where cell swelling results in rupture of the cell membrane and release of intracellular 281 components into the surrounding tissue (reviewed in (55, 56)). In line with this hypothesis, 282
necroptosis markers have been observed in MS lesions (57) and the intrathecally produced 283
antibodies characteristic of persons with MS often are directed against ubiquitous intracellular 284
proteins (58). The role of these anti-nuclear antigen B-cell responses are less clear. Since the 285 antibodies directed against nuclear antigens probably do not have any neutralizing effect on 286 the viruses, they would not protect against infection, reactivation or dissemination. An anti-287
IEA response might be seen as a marker of both increased infection and increased tissue 288 destruction and their function might be to clear cell debris. The relevance of these antibodies, 289
protective or detrimental, in infections and regarding the association with autoimmune disease 290 is yet to be determined. 291
Due to the high similarity and potential antibody cross-reactivity between HHV-6A and 292
HHV-6B, methods discriminating between their serological responses have been difficult to 293 develop. The IE1A and IE1B sequences used in our assay align to some extent ( Figure S9 and 294 Table S6 in Supplementary Material) and the possibility of cross-reactivity should not be 295 neglected. However, the lack of correlation between the IE1A and IE1B serological 296 measurements ( Figure S6 in Supplementary Material) in combination with their associations 297 with MS in opposite directions ( Table 1 and 2), suggests that the method indeed has the 298 potential to discriminate between HHV-6A and HHV-6B. Validating the method using serum 299 from children with primary infection further supported this notion, where seroconversion after 300 primary HHV-6B infection was seen for IE1B and 101K only ( The IE1A antigen had the strongest HLA association in comparison with the other antigens 320 investigated, but this might only reflect the ability of the HLA systems to respond differently 321 to different infections on a population level. Furthermore, individuals respond differently to 322 antigens from the same virus ( Figure S6B in Supplementary Material). Difference in protein 323 structure, location, phase of expression, and function for the IE1 or 101K proteins (37) 324 possibly makes the immune system encounter them under divergent conditions. 325
In the present study we could confirm some of our previously data using the HHV-6B lysate 326 based commercial ELISA, namely lower serological response against HHV-6B lysate (32) 327 and the 101K protein in males and in HLA-A*02 carriers. Female sex has been associated 328
with increased acquisition of HHV-6B in children (5), and it is possible that the HHV-6B 329 lysate IgG (32) and 101K IgG responses reflect this difference in primary HHV-6B infection. 330
The association with HLA-A*02, found in our previous study (32) and suggestively 331 confirmed for anti-101K IgG response in the present study, indicates a role for CD8+ T cells 332
in the immune response against HHV-6B. In line with this notion, 101K peptides have been 333
shown to be presented by HLA-A*02:01 on HHV-6B infected cells and these cells are 334 recognized and killed by CD8+ T cells (59). One can hypothesize that if infected cells are 335 removed, the systemic viral burden may decrease, thus possibly explaining the lower levels of 336
anti-HHV-6A/6B (32) and anti-101K IgG levels in individuals with the HLA-A*02 allele. 337
In conclusion, we provide strong serological data supporting a role for HHV-6A in MS 338 etiology, though causality, as with all forms of association studies remain to be proven. 339
340

MATERIALS AND METHODS 341
Study subjects 342
Two different patient cohorts were used, one with samples taken during MS disease 343 (Established MS, Table 4 ) and one where samples had been collected before MS onset (pre-344 MS, 
Pre-MS cohort 377
The pre-MS cohort is a prospective case-control study on biobank samples drawn before 378 symptom onset ( were matched for biobank, sex, date of blood sampling and date of birth, in order of 387 decreasing priority. The un-even number of cases and controls was due to dropout of study 388 participants after the matching process, leaving 474 matched sets of cases and controls. 389
Between cases and controls the mean difference in age at sampling and date of serum 390 collection was 65 days and 6 days, respectively. For six individuals there were no matching 391 case or control but these individuals were still included in the analyses. In cases where 392 registry data were incomplete, notably time of onset, the registered data were checked and 393 corrected at one of the contributing center. The study was approved by the Regional Ethical 394
Review Board in Umeå and performed according to the ethical standards of the Declaration of 395
Helsinki. 396 397
Measurement of IgG antibodies 398
For detection of IgG antibodies against the different viral proteins, a multiplex serological 399 assay using beads coated with recombinant glutathione s-transferase (GST) fusions proteins 400 was used. The assay procedure has been described in detail elsewhere (70). In short, antigens 401
were expressed as GST fusion proteins using modified pGEX vectors in E. coli. Four different 402 HHV-6 protein sequences were expressed: HHV-6A and -6B specific regions of the IE1 403 protein, IE1A and IE1B respectively, and a divergent region of the structural protein 101K 404 (HHV-6B) and p100 (HHV-6A) ( Figure S9 and Table S6 in Supplementary Material). The 405 antigen expressing bacteria were lysed, the lysate cleared of insoluble components and 406 thereafter in situ purified on specific polystyrene beads set (SeroMap, Luminex Corporation) 407 coupled to glutathione-casein (GC). Plasma/serum from the study subjects were diluted 408 1:1000 and pre-incubated with GST lysate (71) To control for potential confounders, the antibody responses were analyzed using regression 471 models adjusted for age and sex. The established MS cohort was also adjusted for study 472 design (incidence or prevalence design) in all regression analyses. As the p100 IgG responses 473
were mainly in the technical noise area of the assay, the anti-p100 response was therefore 474 excluded from the analyses. 475
Associations between MS and antibody status were investigated using logistic regression 476 models comparing the MS frequency in strong and weak responders. Individuals with MFI 477 values in the 4 th quartile among controls were regarded as strong responders and individuals 478
with MFI values in 1 st quartile among controls were regarded as weak responders. To get a 479 clear separation between strong and weak responders, the in-between responders (individuals 480
with MFI values in between 25 th and 75 th percentile) were excluded in this analysis. Strong 481 and weak responders may reflect seropositive and seronegative individuals, but true serostatus 482 cannot be determined due to lack of validated control samples. The quartiles were determined 483 separately for the two cohorts and are indicated in Figure 1 . 484
To assess if additive interaction occurred between antibody responses to different viruses and 485 between MS HLA risk alleles and HHV-6 immune response in and MS risk, and between MS 486
HLA risk alleles and antibody response, interaction analyses were performed in the 487 established MS cohort. This was done by calculating the proportion attributable to interaction 488 (AP) using logistic regression analysis, where the odds ratios were calculated in relation to the 489 group with the lowest MS risk (76). 490 Antibody levels were analyzed using linear regression models. The IgG responses were 491 heavily left-skewed. To obtain a more normal distribution, the antibody levels (MFI values) 492
were transformed using a log base 10 transformation prior to statistical analysis. When 493 investigating how MS disease influenced the antibody levels, the models were conducted with 494 unadjusted or adjusted data for potential confounders in order to see if the association 495 between MS and antibody levels remained (Tables S1 and S2 in Supplementary Material). In 496 this analysis, both study cohorts were adjusted for EBV and CMV index and the established 497 MS cohort was also adjusted for carriage of HLA alleles (MS risk alleles HLA-A*02:01, 498
HLA-DRB1*15:01 and the alleles associated with each antibody response indicated in Table  499 3 and Table S3 and S4 in Supplementary Material) . 500
Correlations between antibody measurements were investigated with Spearman correlation 501 tests ( Figures S5 and S6 in Supplementary Material) . 502
The main hypothesis tested in this study is that HHV-6A/6B IgG responses are associated 503 with MS disease. To test this hypothesis, three antibody specificities were measured in two 504 different study cohorts, corresponding to 6 independent tests thus using the Bonferroni 505 correction on an alpha level of 0.05 yields a threshold of 0.008 for significance. When other 506 hypotheses were answered, the same alpha value of 0.008 was regarded as significant. 507 508 GWAS 509
Genotypes for ~720,000 single nucleotide polymorphisms (SNPs) were determined using an 510
Illumina OmniExpress BeadChip for 6,396 MS cases and 5,530 controls from the established 511 MS cohort. SNPs with a minor allele frequency of < 2%, with a call-rate of less than 98% or 512 those which were not in Hardy-Weinberg equilibrium among controls (p < 0.0001) were 513 removed from analysis. Individuals with > 2% failed genotype calls, with increased 514 heterozygosity (> mean + 2 SD), related individuals (increased identity by descent, IBD), or 515 individuals where the recorded sex differed from the genotype result were removed from 516 analysis. Population outliers identified using the SmartPCA program were removed. A 517 principal component analysis was conducted using Eigensoft (77) and five PCA components 518 were used to control for population stratification. Linear regression models investigating the 519 association between SNPs and Log10-transformed IE1A, IE1B and 101K antibody levels 520
were analyzed both separately for MS cases and controls, and for all subjects together, using 521 PLINK v1.9 (78) adjusted for 5 PCA vectors, age, sex, cohort type (and MS disease when all 522
subjects were analyzed together). Logistic regression models, adjusted as the linear regression 523 models, were performed to investigate the association between SNPs and strong or weak 524 response (comparing the 3 rd and 1 st quartile respectively) against IE1A, IE1B, and 101K. 525
Associations for SNPs with p < 5x10 -8 were regarded as significant, but all SNPs with 526 suggestive association (p < 10 -5 ) are reported in Tables S4 and S5 in Supplementary Material.  527 Genome build GRCh37 was used. 528 529 HLA-imputation and Associations with HLA haplotypes 530 HLA allele variants for MHC class I and II were imputed by the software HLA*IMP:02 (79)  531 for 7,063 MS cases and 6,098 controls using genotypes from the MS Replication Chip (80). 532
HHV-6A in MS
This chip densely covered in the MHC region. Associations between HLA alleles and IgG 533 responses against each HHV-6 antigen were determined by linear regression models using R 534 version 3.3.1. Associated alleles were combined into haplotypes using previously reported 535 common haplotypes in the Caucasian population (81). Analyses were stratified by MS 536 affection status, but were also conducted on persons with MS patients together with controls. 537
Models were adjusted for age, sex, cohort type (incidence or prevalence), 6 PCA vectors, and 538
for MS disease status when all subjects were analyzed together. To determine the allele with 539 the strongest effect in each associated haplotype, stepwise conditional analyses were 540 performed. Secondary analyses were made where associated HLA alleles were added as co-541 variables to test for independent associations. 542 HHV-6B anti-101K IgG (C and F). The 1 st and 3 rd quartiles are indicated with dotted lines 870 and solid lines indicate median. 871
543
FIGURE 2 872
Interaction of antibody response against different herpesviruses in association to MS. 873 Odds ratios (OR) and confidence intervals (CI) for IE1A and EBV (A) and IE1A 
